Drug Profile
Granisetron intranasal - Almac Discovery/ProStrakan
Alternative Names: ALM 101; Nasal granisetron - Almac discovery/Archimedes PharmaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Archimedes Pharma
- Developer Kyowa Kirin International
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Chemotherapy-induced-nausea-and-vomiting in United Kingdom (Intranasal)
- 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan
- 16 Dec 2009 Phase-I clinical trials in Chemotherapy induced nausea and vomiting in United Kingdom (Intranasal)